Activation of spinal muscarinic acetylcholine receptors (mAChRs) produces analgesia and inhibits dorsal horn neurons through potentiation of GABAergic/glycinergic tone and inhibition of glutamatergic input. To investigate the mAChR subtypes involved in the inhibitory effect of mAChR agonists on glutamate release, evoked excitatory postsynaptic currents (EPSCs) were recorded in lamina II neurons using whole-cell recordings in rat spinal cord slices. 
Introduction
Acetylcholine muscarinic receptors (mAChRs) play an important role in regulation of nociceptive transmission in the spinal cord.
Receptor autoradiography and immunocytochemistry studies have shown that the highest density of mAChRs in the spinal cord is located in the superficial laminae in both rats and humans (Scatton et al. 1984; Villiger and Faull 1985; Yamamura et al. 1983) . Intrathecal administration of mAChR agonists or acetylcholinesterase inhibitors produces a potent analgesic effect in many different species including rats, mice, and humans (Chen and Pan 2003; Duttaroy et al. 2002; Ellis et al. 1999; Hood et al. 1997; Iwamoto and Marion 1993; Naguib and Yaksh 1994) . Furthermore, the analgesia produced by mAChR agonists or acetylcholinesterase inhibitors is blocked by the mAChR antagonist atropine Yaksh 1994, 1997) . Five mAChR subtypes (M 1 -M 5 )
have been identified, and all of which are G protein-coupled receptors (Bonner 1989; Caulfield and Birdsall 1998) . While M 1 , M 3 , and M 5 subtypes are selectively linked to G q/11 proteins and activate phospholipase C, M 2 and M 4 subtypes are preferentially coupled to the pertussis toxinsensitive G i/o proteins and inhibit adenylyl cyclase (Caulfield and Birdsall 1998; Felder 1995; Wess 1996) . Previous studies have documented that M 2 , M 3 , and M 4 (but not the M 1 ) subtypes are present in the spinal cord dorsal horn Duttaroy et al. 2002; Hoglund and Baghdoyan 1997; Wei et al. 1994; Yung and Lo 1997) . Although the role of the M 2 and M 4 receptor subtypes in the mAChR agonist-induced analgesia has been established (Duttaroy et al. 2002; Ellis et al. 1999; Gomeza et al. 1999) , the mechanisms by which each mAChR subtype contributes to the muscarinic analgesia in the spinal cord are not well understood.
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The spinal lamina II neurons receive glutamatergic excitatory and GABAergic/glycinergic inhibitory inputs. Our previous studies have shown that M 2 , M 3 and M 4 subtypes all contribute to increased GABAergic tone in the rat spinal cord (Zhang et al. 2005) . Also, the M 3 subtype is mainly responsible for potentiation of glycinergic input to spinal dorsal horn neurons in rats (Wang et al. 2006) . Glutamate released from primary afferents is a major excitatory neurotransmitter, which conveys nociceptive information to the superficial dorsal horn neurons (Pan et al. 2002; Yoshimura and Jessell 1990) . It has been shown that stimulation of mAChRs inhibits glutamate release from primary afferents in the rat spinal cord (Li et al. 2002) . However, the mAChR subtypes that contribute to this action are still unclear. In this study, we determined the role of mAChR subtypes in the control of glutamatergic inputs from primary afferents and interneurons to spinal lamina II neurons. Sprague-Dawley rats (3-4 weeks old; Harlan, Indianapolis, IN) were used in this study.
Intrathecal treatment with PTX
To determine the involvement of M 2 /M 4 subtypes in the inhibitory effect of oxotremorine-M on synaptic glutamate release, a group of rats was pre-treated with intrathecal PTX to inactivate inhibitory G i/o proteins (Chen and Pan 2004; Wang et al. 2006) . Intrathecal catheters were inserted in rats anesthetized using 2% isoflurane. The catheters (polyethylene-10 tubing) were inserted through an incision in the cisternal membrane and advanced 4.5 cm caudal so that the tip of each catheter was positioned at the lumbar spinal level. Rats were injected with intrathecal 1 µg of PTX 5-7 days before the final electrophysiology experiments.
Spinal cord slice preparations
Rats were anesthetized with 2% isoflurane in O 2 and the lumbar segment of the spinal cord was rapidly removed through a limited laminectomy. The rats then were killed by inhalation of 5% isoflurane. The segment of the lumbar spinal cord was immediately placed in an ice-cold sucrose artificial cerebrospinal fluid (aCSF) pre-saturated with 95% O 2 and 5% CO 2 .
The sucrose aCSF contained (mM): sucrose, 234; KCl, 3.6; MgCl 2 , 1.2; CaCl 2 , 2.5; NaH 2 PO 4 , 1.2; glucose, 12.0; and NaHCO 3 , 25.0. The tissue was then placed in a shallow groove formed in Recordings of postsynaptic currents were performed using the whole-cell voltage-clamp method, as we described previously (Li et al. 2002; Zhang et al. 2005) . The neurons located in lamina II in the spinal slice were identified under a fixed-stage microscope (BX50WI, Olympus, Tokyo, Japan) with differential interference contrast/infrared illumination. The electrode for the wholecell recordings was pulled from borosilicate glass capillaries with a puller (P-97, Sutter
Instrument, Novato, CA). The impedance of the pipette was 3-5 MN when filled with internal solution containing (mM): K-gluconate 135; KCl, 5; MgCl 2 , 2.0; CaCl 2 , 0.5; HEPES, 5.0; EGTA, 5.0; ATP-Mg, 5.0; Na-GTP, 0.5; and guanosine 5'-O-(2-thiodiphosphate) (GDP-ß-S), 1; QX314 10; adjusted to pH 7.2-7.4 with 1 M KOH (290-320 mOsm). GDP-ß-S was added to the internal solution to block the possible postsynaptic effect mediated by mAChR agonists through G proteins (Li et al. 2002; Zhang et al. 2005) . QX314 was added to the internal solution to suppress the action potential generation from the recorded cell. The slice was placed in a glass- JN-00586-2006 8
Electrophysiological recordings
The evoked excitatory postsynaptic currents (eEPSCs) were induced by electrical stimulation (0.3 ms, 0.2-0.5 mA and 0.2 Hz) of the dorsal root or dorsal root entry zone. The eEPSCs or spontaneous EPSCs (sEPSCs) were recorded in the presence of 2 µM strychnine (a glycine receptor antagonist) and 10 µM bicuculline (GABA A receptor antagonist). Because activation of mAChRs increases spinal GABA release (Li et al. 2002; Zhang et al. 2005 ), which in turn activates presynaptic GABA B receptors to depress presynaptic glutamate release (Li et al. 2002) , the GABA B receptor antagonist CGP55845 (2 µM) was also bath applied in all the protocols. We started to record eEPSCs or sEPSCs after ~ 5 min after whole-cell access was established and the EPSCs reached a steady state. To record the miniature EPSCs (mEPSCs), 1 µM tetrodotoxin (TTX) was added in the perfusion solution. The input resistance was monitored and the recording was abandoned if it changed more than 15% (Li et al. 2002; Pan et al. 2002) .
Signals were recorded using an amplifier (MultiClamp700A, Axon Instruments, Foster City, CA)
at a holding potential of -70 mV, filtered at 1-2 kHz, digitized at 10 kHz, and stored into a Pentium computer with pCLAMP 9.0 (Axon Instruments).
Oxotremorine-M, himbacine, AFDX-116, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), GDP-ß-S, strychnine, CNQX, and bicuculline were obtained from Sigma-Aldrich (St. Louis, MO). PTX was purchased from List Biological Laboratories (San Jose, CA). QX314 and TTX were obtained from Alomone Labs (Jerusalem, Israel). CGP55845
was obtained from Tocris (Ellisville, MO). Muscarinic toxin-3 (MT-3) was purchased from
Peptide Institute, Inc (Osaka, Japan). Drugs were dissolved in Krebs solution and perfused into the slice chamber using syringe pumps.
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Data analysis
Data are presented as means ± SEM. The peak amplitude of eEPSCs were analyzed using Clampfit (Axon Instrument). Measurements of the peak amplitude of eEPSCs were performed by averaging of 10 consecutive eEPSCs at 0.2 Hz during control, drug application, and recovery.
The effects of oxotremorine-M on the peak amplitude of eEPSCs were determined by paired two-tailed Student's t-test or one-way ANOVA. The sEPSCs and mEPSCs were analyzed offline with a peak detection program (MiniAnalysis, Synaptosoft, Leonia, NJ). Neurons were considered to be responsive to oxotremorine-M if the peak amplitude of eEPSCs or the frequency of sEPSCs and mEPSCs was altered > 20% (Wang et al. 2006; Zhang et al. 2006) . P < 0.05 was considered to be statistically significant.
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Results
Effect of oxotremorine-M on glutamate release evoked from primary afferents
To determine the effect of oxotremorine-M on glutamate release from primary afferents to lamina II neurons, the effect of oxotremorine-M on identified monosynaptic and polysynaptic eEPSCs were studied. The eEPSCs was considered to be monosynaptic if: 1) the latency was constant following electrical stimulation (0.2 Hz), and 2) there was no conduction failure or increased latency for monosynaptic eEPSCs when stimulation frequency was increased to 20 Hz (Li et al. 2002) , although the amplitude of eEPSCs was markedly attenuated at 20 Hz (Fig. 1A ).
In contrast, the latency of polysynaptic eEPSCs was variable and conduction failure occurred at the higher stimulation frequency (20 Hz, Fig. 1B ). Because the recordings were made in the outer zone of lamina II, we observed that 60% -70% of the eEPSCs were monosynaptic.
To determine the concentration-dependent effect of oxotremorine-M on eEPSCs, 1, 3, 5
and 10 µM oxotremorine-M, a mAChR agonist that is non-selective for mAChR subtypes, was perfused in an accumulative fashion to the tissue chamber. Each concentration of oxotremorine-M was applied for a duration of 3 min. As shown in Fig significantly greater inhibition on polysynaptic eEPSCs than on monosynaptic eEPSCs (Fig. 2C ).
The eEPSCs were completely abolished by 20 SM CNQX, a non-NMDA receptor antagonist, indicating that eEPSCs were mediated by glutamate non-NMDA receptors.
Effect of oxotremorine-M on eEPSCs in PTX-treated rats
To investigate the contribution of M 2 /M 4 subtypes to the effect of the mAChR agonist on synaptic glutamate release to lamina II neurons, rats were pre-treated with intrathecal 1 µg PTX to inactivate inhibitory G i/o proteins 5-7 days before final electrophysiology experiments.
Oxotremorine-M (1-10 µM) failed to alter the peak amplitude of monosynaptic eEPSCs in all 12 cells tested (Fig. 3A) . Oxotremorine-M significantly inhibited the peak amplitude of polysynaptic eEPSCs from 228.9 ± 28.6 to 129.5 ± 19.8 pA in 7 of 16 cells (44%, Fig. 3B ), but it did not significantly alter the peak amplitude of polysynaptic eEPSCs in another 9 cells (56%, Fig. 3C ).
To delineate if the M 3 subtype mediates the remaining effect of oxotremorine-M on polysynaptic eEPSCs, 4-DAMP, a relatively selective M 3 subtype antagonist (Ehlert 1996; Yigit et al. 2003; Zhang et al. 2006; Zhang et al. 2005) , was used. The inhibitory effect of 5 µM oxotremorine-M on polysynaptic eEPSCs was blocked by 50 nM 4-DAMP (n = 7, Fig. 3B ).
These results suggest that M 2 /M 4 subtypes are probably responsible for the muscarinic inhibition of synaptic glutamate release from the primary afferents and a subpopulation of interneurons in the spinal cord. The M 3 subtype present on a subpopulation of interneurons in the spinal cord also contributes to inhibition of glutamatergic synaptic transmission.
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Role of M 2 and M 4 subtypes in the effect of oxotremorine on monosynaptic eEPSCs
To delineate the role of M 2 /M 4 subtypes in the inhibitory effect of oxotremorine-M on glutamate release from primary afferents to lamina II neurons, himbacine, a relatively selective antagonist for M 2 /M 4 subtypes (Doller et al. 1999; Dorje et al. 1991; Miller et al. 1992; Zhang et al. 2005) , was perfused 3 min before re-application of oxotremorine-M. In our previous studies using spinal cord slices from rats and muscarinic receptor knockout mice ( Application of 10 SM AFDX-116 abolished the inhibitory effect of oxotremorine-M on the peak amplitude of monosynaptic eEPSCs in all 11 cells tested (Fig. 4B ).
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Because AFDX-116 at the concentration used in this study may also act on the M 4 subtype (Caulfield and Birdsall 1998) , we also assessed the potential role of the M 4 subtype in the inhibitory effect of oxotremorine-M on monosynaptic eEPSCs. MT-3, a specific M 4 subtype antagonist, was studied in another 9 cells. MT-3 has a greater than 500-fold selectivity for the M 4 over M 2 , M 3 , and M 5 subtypes (Jolkkonen et al. 1994; Liang et al. 1996) . As shown in 
Effect of oxotremorine-M on sEPSCs and mEPSCs in spinal lamina II neurons
The effect of oxotremorine-M on the frequency of sEPSCs was determined in 22 lamina II neurons. In 15 of 22 neurons, 5 SM oxotremorine-M had no significant effect on the frequency of sEPSCs (Fig. 6A ). In the rest of 7 (31.8%) cells, 5 SM oxotremorine-M significantly decreased the frequency of sEPSCs from 3.4 ± 0.6 to 2.1 ± 0.4 Hz (Fig. 6B) . In 4 of these 7 cells tested, subsequent application of 50 nM 4-DAMP blocked the inhibitory effect of 5 SM oxotremorine-M on the frequency of sEPSCs (from 2.6 ± 0.8 to 2.5 ± 0.8 Hz). However, oxotremorine-M had no significant effect on mEPSCs in all 9 cells recorded (from 9.8 ± 1.8 to 9.2 ± 1.8 Hz). These results suggest that activation of the M 3 subtype inhibits synaptic glutamate release from a subpopulation of glutamatergic interneurons in the spinal dorsal horn.
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Discussion
In the present study, we found that the mAChR agonist oxotremorine-M produced a greater inhibition of polysynaptic eEPSCs than monosynaptic eEPSCs. In rats pre-treated with intrathecal PTX, oxotremorine-M failed to decrease the monosynaptic eEPSCs but still had a partial inhibitory effect on polysynaptic eEPSCs in some neurons. subtypes are particularly concentrated in the superficial laminae of the spinal cord (Hoglund and Baghdoyan 1997; Li et al. 2002; Yung and Lo 1997) . Also, there is a small but functionally significant M 4 subtype in the spinal cord . The excitability of spinal dorsal horn neurons are tonically controlled by glutamatergic excitatory and GABAergic/glycinergic inhibitory inputs. Our previous studies have shown that M 2 , M 3 , and M 4 subtypes all contribute to increased GABAergic tone in the rat spinal cord (Zhang et al. 2005) . Furthermore, the M 3 subtype is responsible for potentiation of glycinergic input to dorsal horn neurons in rats (Wang et al. 2006) . Glutamate released from primary afferents is a major excitatory neurotransmitter, which conveys nociceptive information to the superficial dorsal horn neurons (Yoshimura and Jessell 1990) . Jolkkonen et al. 1994; Liang et al. 1996) were used in this study.
We found that AFDX-116 abolished the effect of oxotremorine-M on monosynaptic eEPSCs in all cells tested. By contrast, MT-3 failed to attenuate the effect of oxotremorine-M on monosynaptic eEPSCs. Therefore, these findings strongly suggest that the M 2 , but not M 4 , In the present study, we found unexpectedly that the inhibitory effect of oxotremorine-M on polysynaptic eEPSCs was much greater than that on monosynaptic eEPSCs. These results suggest that mAChRs are located not only on primary afferent terminals but also on glutamatergic interneurons. Since the effect of oxotremorine-M on polysynaptic eEPSCs was not abolished by PTX and himbacine in some neurons, mAChR subtypes that are not coupled to PTX-sensitive G i/o proteins (i.e., non-M 2 /M 4 ) may be present on a subpopulation of glutamatergic interneurons. The radioligand binding study suggests that the M 3 subtype is present in the rat spinal cord (Hoglund and Baghdoyan 1997) . We have shown that the M 3 subtype is involved in the potentiation of both GABA (Zhang et al. 2005 ) and glycine release (Wang et al. 2006 ) from interneurons in the rat spinal cord. In the current study, we found that the remaining inhibitory effect of oxotremorine-M on polysynaptic eEPSCs in PTX-treated rats was blocked by a relatively selective M 3 antagonist 4-DAMP. Hence, the M 3 subtype is also likely involved in the inhibition of synaptic glutamate release from some glutamatergic interneurons in the spinal cord.
In support of this conclusion, the effect of oxotremorine-M on polysynaptic eEPSCs in the presence of himbacine in some neurons was abolished by 4-DAMP. Importantly, while oxotremorine-M had no effect on mEPSCs in all cells tested, it decreased the frequency of sEPSCs in 31.8% lamina II neurons, an effect that was blocked by 4-DAMP. Collectively, these results suggest that the M 3 as well as M 2 /M 4 subtypes play a role in regulation of synaptic glutamate release from the interneurons in the spinal cord. Because oxotremorine-M had no significant effect on mEPSCs in all neurons tested, these electrophysiological data suggest that the M 3 and M 2 /M 4 subtypes are probably located on the somatodendritic site of the interneurons.
It should be noted that although the M 2 and M 4 subtypes are essential for the analgesic effect of mAChR agonists in mice (Duttaroy et al. 2002; Gomeza et al. 1999) , the functional role of the M 3 subtype in the spinal analgesic effect of mAChRs agonists remains to be defined.
The M 2 subtype is coupled to the G i/o protein, which inhibits adenylate cyclase activity (Caulfield 1993; Fields and Casey 1997; Wess 1996) . Thus, activation of the M 2 subtype is expected to depress the synaptic glutamate release in the spinal cord. However, the M 3 subtype is mainly coupled to the G q/11 protein to activate phospholipase C (Caulfield 1993; Fields and Casey 1997; Wess 1996) . Its inhibitory effect on synaptic glutamate release in the spinal cord is not anticipated. The signaling mechanism underlying the inhibitory effect of the M 3 subtype on synaptic glutamate release in the spinal cord is not well understood. It has been shown that stimulation of the M 3 subtype reduces excitatory synaptic transmission in dopaminergic neurons of the rat mesencephalon (Grillner et al. 1999) . Also, activation of the M 3 subtype inhibits both excitatory and inhibitory transmission in rat subthalamic neurons in vitro (Shen and Johnson 2000) . Activation of the M 3 subtype produces a K + current (I KM3 ), which is G q protein-coupled, delayed rectifier-like K + current (Shi et al., 1999; Shi et al., 2004) . Opening of these potassium channels can cause membrane hyperpolarization and action potential duration shortening (Shi et al. 2003 ). This could be a possible mechanism responsible for, at least in part, the inhibitory effect of the M 3 subtype on glutamatergic interneurons in the spinal cord.
It is worth noting that many antagonists used in this study have limited selectivity for mAChR subtypes. In our previous study using the rat spinal cord, we have extensively tested and determined the minimal concentrations of the antagonists (himbacine, 4-DAMP, and AFDX-116) by using various combinations of the drugs and PTX treatment (Wang et al. 2006; Zhang et al. 2005 ). Furthermore, using muscarinic receptor knockout (KO) mice, we have clearly demonstrated that activation of M 2 /M 4 subtypes and the M 3 subtype produces an opposite effect on GABAergic sIPSCs in the spinal dorsal horn . In the mouse spinal cord, these distinct functions of M 2 /M 4 and M 3 subtypes are the basis to determine the selectivity of various muscarinic subtype antagonists . Duttaroy et al. 2002; Gomeza et al. 1999; Hoglund and Baghdoyan 1997) .
Thus, the confounding effect of 4-DAMP on M 1 and M 5 subtypes is not a critical concern to this particularly study using the spinal cord slice. Using M 2 /M 4 double-KO mice, we have determined that 25-50 nM 4-DAMP is the minimal concentration that abolishes the effect of 3-5 µM oxotremorine-M on GABA release . To minimize the possibility that 4-DAMP may interfere with the M 2 and M 4 subtypes in the spinal cord, 4-DAMP was the last JN-00586-2006 20 antagonist perfused to the spinal slices in our protocol. Although AFDX-116 has a higher affinity for M 2 than M 4 subtypes (Caulfield and Birdsall 1998) , this antagonist at the concentration used may also act on the M 4 subtype in the spinal cord. Therefore, we used a more specific M 4 subtype antagonist, MT-3 (Jolkkonen et al. 1994; Liang et al. 1996) , to delineate the role of M 2 and M 4 subtypes in the effect of oxotremorine-M on monosynaptic eEPSCs. We found that 100 nM MT-3 failed to alter the inhibitory effect of oxotremorine-M on monosynaptic eEPSCs, although it significantly attenuates the effect of oxotremorine-M on GABA release (Zhang et al. 2005) . These data provide strong evidence that the M 2 , but not M 4 , subtype is present on the primary afferent terminals.
In summary, we found in this study that the M 2 subtype controls the synaptic glutamate release from the primary afferents in the spinal cord (Fig. 7) . Furthermore, our data suggest that the M 3 and M 2 /M 4 subtypes are involved in regulation of glutamate release from a subpopulation of interneurons in the rat spinal cord (Fig. 7) . Therefore, the present and other recent studies (Wang et al. 2006; Zhang et al. 2005) 
